PDF(Pubmed)
Abstract：
UNASSIGNED: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy.
UNASSIGNED: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies reporting our pre-specified outcomes.
UNASSIGNED: It was observed that mavacamten significantly improved New York Heart Association class (p < 0.009), Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (p = 0.02), post-exercise left ventricular outflow tract gradient (p < 0.00001), functional end point (p = 0.05), and lowered septal reduction therapy rates (p < 0.00001). However, there were no significant differences in the ≥1 severe adverse events, ≥1 treatment-emergent adverse events, left ventricular volume index, left ventricular filling pressure, left ventricular end-diastolic volume index, and peak oxygen uptake (pVO2).
UNASSIGNED: Future large-scale trials are required to confirm our results and determine the long-term benefits and risks of mavacamten use in these patients.
Mavacamten is a recently introduced medication that relaxes the heart muscle and is indicated for patients with hypertrophic cardiomyopathy (a disease in which parts of the heart become thick and stiff). To determine the effectiveness and safety of this drug, the results of clinical trials were combined in order to produce an overall estimate. Overall, it was observed that mavacamten improved most functional parameters related to the heart and demonstrated no significant increases in the number of side effects. This suggests the effectiveness and safety of mavacamten, although further trials are needed to confirm our results.
UNASSIGNED: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies reporting our pre-specified outcomes.
UNASSIGNED: It was observed that mavacamten significantly improved New York Heart Association class (p < 0.009), Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (p = 0.02), post-exercise left ventricular outflow tract gradient (p < 0.00001), functional end point (p = 0.05), and lowered septal reduction therapy rates (p < 0.00001). However, there were no significant differences in the ≥1 severe adverse events, ≥1 treatment-emergent adverse events, left ventricular volume index, left ventricular filling pressure, left ventricular end-diastolic volume index, and peak oxygen uptake (pVO2).
UNASSIGNED: Future large-scale trials are required to confirm our results and determine the long-term benefits and risks of mavacamten use in these patients.
Mavacamten is a recently introduced medication that relaxes the heart muscle and is indicated for patients with hypertrophic cardiomyopathy (a disease in which parts of the heart become thick and stiff). To determine the effectiveness and safety of this drug, the results of clinical trials were combined in order to produce an overall estimate. Overall, it was observed that mavacamten improved most functional parameters related to the heart and demonstrated no significant increases in the number of side effects. This suggests the effectiveness and safety of mavacamten, although further trials are needed to confirm our results.
摘要：
■这项荟萃分析是为了评估mavacamten在肥厚型心肌病患者中的疗效和安全性。
■使用PubMed进行了搜索，科克伦,和Scopus截至2022年8月的随机研究报告我们预先指定的结果。
■观察到mavacamten显着改善了纽约心脏协会等级（p<0.009），堪萨斯城心肌病问卷的临床总结评分（p=0.02），运动后左心室流出道梯度（p<0.00001），功能终点（p=0.05），并降低了中隔减少治疗率（p<0.00001）。然而,≥1次严重不良事件无显著差异，≥1例治疗引起的不良事件，左心室容积指数,左心室充盈压,左心室舒张末期容积指数,和峰值摄氧量(pVO2)。
■需要进行未来的大规模试验，以确认我们的结果，并确定在这些患者中使用mavacampen的长期益处和风险。
Mavacamten是最近推出的一种放松心肌的药物，适用于肥厚型心肌病（一种心脏部分变厚变硬的疾病）患者。为了确定这种药物的有效性和安全性，将临床试验的结果合并以得出总体估计.总的来说,观察到mavacampen改善了与心脏相关的大多数功能参数，并且没有显示副作用数量的显着增加。这表明mavacampen的有效性和安全性，尽管需要进一步的试验来证实我们的结果.
■使用PubMed进行了搜索，科克伦,和Scopus截至2022年8月的随机研究报告我们预先指定的结果。
■观察到mavacamten显着改善了纽约心脏协会等级（p<0.009），堪萨斯城心肌病问卷的临床总结评分（p=0.02），运动后左心室流出道梯度（p<0.00001），功能终点（p=0.05），并降低了中隔减少治疗率（p<0.00001）。然而,≥1次严重不良事件无显著差异，≥1例治疗引起的不良事件，左心室容积指数,左心室充盈压,左心室舒张末期容积指数,和峰值摄氧量(pVO2)。
■需要进行未来的大规模试验，以确认我们的结果，并确定在这些患者中使用mavacampen的长期益处和风险。
Mavacamten是最近推出的一种放松心肌的药物，适用于肥厚型心肌病（一种心脏部分变厚变硬的疾病）患者。为了确定这种药物的有效性和安全性，将临床试验的结果合并以得出总体估计.总的来说,观察到mavacampen改善了与心脏相关的大多数功能参数，并且没有显示副作用数量的显着增加。这表明mavacampen的有效性和安全性，尽管需要进一步的试验来证实我们的结果.
